Intersect ENT (Intersect ENT) Total Current Liabilities : $46.4 Mil (As of Mar. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Intersect ENT Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Intersect ENT's total current liabilities for the quarter that ended in Mar. 2022 was $46.4

Intersect ENT Total Current Liabilities Historical Data

The historical data trend for Intersect ENT's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intersect ENT Total Current Liabilities Chart

Intersect ENT Annual Data

Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21

Total Current Liabilities

Get a 7-Day Free Trial 17.68 19.73 18.94 44.25 57.16

Intersect ENT Quarterly Data

Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22

Total Current Liabilities Get a 7-Day Free Trial 43.54 45.40 50.79 57.16 46.41

Intersect ENT Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Intersect ENT's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 8.888 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 31.259 + 17.013

= 57.2

Intersect ENT's Total Current Liabilities for the quarter that ended in Mar. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 9.179 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 20.563 + 16.671

= 46.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Intersect ENT Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Intersect ENT's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Intersect ENT (Intersect ENT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Intersect ENT Inc (NAS:XENT) » Definitions » Total Current Liabilities

Comparable Companies

VREX TMCI KIDS CERS HSKA OM SILK CUTR ATEC TMDX ABT MDT SYK EW BSX SZSE:300760 DXCM ZBH STE ALGN

Traded in Other Exchanges

N/A

Address

1555 Adams Drive, Menlo Park, CA, USA, 94025

Website

https://www.intersectent.com

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.

Executives

Elisabeth Sandoval director C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362

Neil A Hattangadi director 1555 ADAMS DRIVE MENLO PARK CA 94025

Reyna M Fernandez officer: Chief Human Resource Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025

Patrick A Broderick officer: EVP, GC & Corporate Secretary C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025

Thomas A. West director, officer: President and CEO C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025

Richard A Meier officer: EVP & Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025

Binney Robert H Jr officer: Vice President, Sales 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025

Susan P Stimson officer: Vice President, Marketing 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025

Lisa D Earnhardt director, officer: See Remarks 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025

David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025

Jeryl L Hilleman officer: Chief Financial Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025

Christine R Kowalski officer: Chief Operations Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025

Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025

Richard E Kaufman officer: See Remarks 1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025

Gwen R. Carscadden officer: Chief People Officer C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025

Intersect ENT (Intersect ENT) Headlines

From GuruFocus

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Intersect ENT, Inc. Buyout
By Marketwired Marketwired • 08-06-2021

Intersect ENT to Report First Quarter 2021 Financial Results
By Business Wire Business Wire • 04-20-2021

EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL� Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
By Business Wire Business Wire • 04-29-2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
By PRNewswire PRNewswire • 09-13-2021

INTERSECT ENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intersect ENT - XENT
By Business Wire Business Wire • 08-06-2021

Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020
By Business Wire Business Wire • 01-12-2021

Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm � XENT
By Business Wire Business Wire • 08-06-2021

(XENT Alert) Johnson Fistel Investigates Proposed Sale of Intersect ENT; Is $28.25 a Fair Price?
By PRNewswire PRNewswire • 08-07-2021

Intersect ENT to Participate at Upcoming Investor Conferences
By Business Wire Business Wire • 05-07-2021

Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference
By Business Wire Business Wire • 12-18-2020

Intersect ENT Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Total Current Liabilities	Get a 7-Day Free Trial															43.54	45.40	50.79	57.16	46.41

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	8.888	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	31.259	+	17.013
	=	57.2

Elisabeth Sandoval	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Neil A Hattangadi	director	1555 ADAMS DRIVE MENLO PARK CA 94025
Reyna M Fernandez	officer: Chief Human Resource Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Patrick A Broderick	officer: EVP, GC & Corporate Secretary	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Thomas A. West	director, officer: President and CEO	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Richard A Meier	officer: EVP & Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Binney Robert H Jr	officer: Vice President, Sales	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Susan P Stimson	officer: Vice President, Marketing	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Lisa D Earnhardt	director, officer: See Remarks	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Jeryl L Hilleman	officer: Chief Financial Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Christine R Kowalski	officer: Chief Operations Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Richard E Kaufman	officer: See Remarks	1555 ADAMS DRIVE C/O INTERSECT ENT, INC. MENLO PARK CA 94025
Gwen R. Carscadden	officer: Chief People Officer	C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025